Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Discussions regarding the Omnibus Spending Bill (H.R.1 - PL 115-97)
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2018 · second_quarter · 2T
Discussions regarding opioid abuse Discussions regarding 340B drug discount program Food & Drug Cosmetics Act Drug pricing
Discussions regarding the Omnibus Spending Bill (H.R.1 - PL 115-97)
Source: Senate LDA
Discussions regarding the Omnibus Spending Bill (H.R.1 - PL 115-97)
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Discussions regarding opioid abuse Discussions regarding 340B drug discount program S.974,Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act of 2017) Discussions regarding PBM patient assistance limitations
Medical Product Communications Act of 2017
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Discussions regarding the Affordable Health Care Act (ACA) H.R.1703, Medical Product Communications Act of 2017
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 H.R.2430 and S.934, FDA Reauthorization Act of 2017
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 Discussions regarding opioid abuse Discussions regarding 340B drug discount program
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 Discussions regarding opioid abuse Discussions regarding 340B drug discount program
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 H.R.2430 and S.934, FDA Reauthorization Act of 2017
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 H.R.2430 and S.934, FDA Reauthorization Act of 2017
Food and Drug Administration Reform Act of 2012
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Discussions related to drug importation and IPAB; Discusions regarding Prescription Drug User Fee Act (PDUFA) (no bill #); Discussions regarding healthcare reform; Discussions regarding the Food and Drug Administration Reform Act (H.R. 5651); Discussions regarding the Food and Drug Administration Safety and Innovation Act (S.3187).
Food and Drug Administration Reform Act of 2012
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Discussions related to drug importation and IPAB; Discusions regarding Prescription Drug User Fee Act (PDUFA) (no bill #); Discussions regarding healthcare reform; Discussions regarding the Food and Drug Administration Reform Act (H.R. 5651); Discussions regarding Drug Safety and Accountability Act (S.1584)
Medicare Decisions Accountability Act of 2010
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R. 759 - Food and Drug Administration Globalization Act of 2009, all provisions H.R. 4985 - Medicare Decisions Accountability Act of 2010, all provisions Discussions regarding drug product importation
Food and Drug Administration Globalization Act of 2009
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R. 759 - Food and Drug Administration Globalization Act of 2009, all provisions H.R. 4985 - Medicare Decisions Accountability Act of 2010, all provisions Discussions regarding drug product importation
American Middle Class Tax (AMT) Relief Act of 2007
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R. 3590 - The Patient Protection and Affordable Care Act; issues relating to drug importation.
American Middle Class Tax (AMT) Relief Act of 2007
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R. 3590 - The Patient Protection and Affordable Care Act; issues relating to drug importation.
H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R. 3590 - The Patient Protection and Affordable Care Act; issues relating to drug importation.
H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R. 3590 - The Patient Protection and Affordable Care Act; issues relating to drug importation.
Comparative Effectiveness Research Act of 2009
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R. 3200 - America's Affordable Health Choices Act of 2009, provisions related to importation of drugs; H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R.2502 - Comparative Effectiveness Research Act of 2009, all provisions; S. 525 - Pharmaceutical Market Access and Drug Safety Act of 2009, provisions related to drug importation; H.R. 3590 - The Patient Protection and Affordable Care Act; S.1796 - America's Healthy Future Act
America's Affordable Health Choices Act of 2009
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R. 3200 - America's Affordable Health Choices Act of 2009, provisions related to importation of drugs; H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R.2502 - Comparative Effectiveness Research Act of 2009, all provisions; S. 525 - Pharmaceutical Market Access and Drug Safety Act of 2009, provisions related to drug importation; H.R. 3590 - The Patient Protection and Affordable Care Act; S.1796 - America's Healthy Future Act
H.R. 3200 - America's Affordable Health Choices Act of 2009, provisions related to importation of drugs; H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R.2502 - Comparative Effectiveness Research Act of 2009, all provisions; S. 525 - Pharmaceutical Market Access and Drug Safety Act of 2009, provisions related to drug importation; H.R. 3590 - The Patient Protection and Affordable Care Act; S.1796 - America's Healthy Future Act
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R. 3200 - America's Affordable Health Choices Act of 2009, provisions related to importation of drugs; H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R.2502 - Comparative Effectiveness Research Act of 2009, all provisions; S. 525 - Pharmaceutical Market Access and Drug Safety Act of 2009, provisions related to drug importation; H.R. 3590 - The Patient Protection and Affordable Care Act; S.1796 - America's Healthy Future Act
Family Smoking Prevention and Tobacco Control Act
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
S. 982 - Family Smoking Prevention & Tobacco Control Act (issues related to drug product importation amendment) General issues related to drug product importation
American Middle Class Tax (AMT) Relief Act of 2007
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
H.R. 3200 - America's Affordable Health Choices Act of 2009, provisions related to importation of drugs; H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R.2502 - Comparative Effectiveness Research Act of 2009, all provisions; S. 525 - Pharmaceutical Market Access and Drug Safety Act of 2009, provisions related to drug importation; H.R. 3590 - The Patient Protection and Affordable Care Act; S.1796 - America's Healthy Future Act
H.R. 3200 - America's Affordable Health Choices Act of 2009, provisions related to importation of drugs; H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R.2502 - Comparative Effectiveness Research Act of 2009, all provisions; S. 525 - Pharmaceutical Market Access and Drug Safety Act of 2009, provisions related to drug importation; H.R. 3590 - The Patient Protection and Affordable Care Act; S.1796 - America's Healthy Future Act
Discussions regarding Medicare, IPAB, and Part D and Part B
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2018 · first_quarter · Q1
Discussions regarding opioid abuse Discussions regarding 340B drug discount program S.974,Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act of 2017) Discussions regarding PBM patient assistance limitations
Discussions regarding the Omnibus Spending Bill (H.R.1 - PL 115-97)
Discussions regarding Medicare, IPAB, and Part D and Part B
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2017 · fourth_quarter · Q4
Discussions regarding the Affordable Health Care Act (ACA)
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 Discussions regarding opioid abuse Discussions regarding 340B drug discount program
Discussions regarding Medicare, IPAB, and Part D
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2017 · third_quarter · Q3
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 Discussions regarding opioid abuse Discussions regarding 340B drug discount program
Discussions regarding the Affordable Health Care Act (ACA)
Discussions regarding Medicare and Medicaid
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2017 · second_quarter · Q2
Discussions regarding the Affordable Health Care Act (ACA) H.R.1703, Medical Product Communications Act of 2017
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 H.R.2430 and S.934, FDA Reauthorization Act of 2017
Discussions regarding Medicare
Filing targets: HOUSE OF REPRESENTATIVES
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2017 · first_quarter · Q1
Discussions regarding Medicare
Discussions regarding the Affordable Health Care Act (ACA) Tax reform as it relates to healthcare Discussions regarding Anti-Kickback statute
Discussions regarding corporate tax reform
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2016 · fourth_quarter · Q4
Discussions regarding the Affordable Care Act (ACA) Discussions regarding drug disposal Discussions regarding 21st Century Cures Act Discussions regarding 340B Drug Program Discussions regarding Medication Pricing Information (MPI) Discussions regarding prescription drug abuse
Discussions regarding Medicare
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2016 · second_quarter · 2A
Discussions regarding Medicare
Discussions regarding the Affordable Care Act (ACA) Discussions regarding prescription drug abuse Discussions regarding Drug sales information reporting (DSIR) Discussions regarding Food Drug & Cosmetic Act Discussions regarding 340B Drug Program
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2016 · third_quarter · Q3
Discussions regarding Medicare and Medicaid
Discussions regarding the Affordable Care Act (ACA) Discussions regarding Drug sales information reporting (DSIR) Discussions regarding Food Drug & Cosmetic Act Discussions regarding 340B Drug Program Discussions regarding generic drug pricing
Filing targets: HOUSE OF REPRESENTATIVES
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2016 · second_quarter · Q2
Discussions regarding the Affordable Care Act (ACA) Discussions regarding prescription drug abuse Discussions regarding Drug sales information reporting (DSIR) Discussions regarding Food Drug & Cosmetic Act Discussions regarding 340B Drug Program
Discussions regarding Medicare
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2016 · first_quarter · Q1
Discussions regarding the Affordable Care Act (ACA) Discussions regarding prescription drug abuse Discussions regarding Prescription Drug User Act Fee
Discussion regarding Trans Pacific Partnership agreement
Discussions regarding Medicare
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2015 · fourth_quarter · Q4
Discussions regarding the Affordable Care Act (ACA) Discussions regarding Food, Drug & Cosmetic Act (FDCA)
Discussions regarding Patent reform
Discussions regarding Medicare and 340B Drug Discount Program
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2015 · third_quarter · Q3
Discussions regarding Patent reform
Discussions regarding the Affordable Care Act (ACA) Discussions regarding the 21st Century Cures Act Discussions regarding Food, Drug & Cosmetic Act (FDCA)
Discussions regarding Medicare and 340B Drug Discount Program
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2015 · second_quarter · Q2
Discussions regarding the Affordable Care Act (ACA) Discussions regarding insurance exchanges Discussions regarding the 21st Century Cures Act
Discussions regarding Medicare and 340B Drug Discount Program
Discussions regarding Patent reform
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2015 · first_quarter · Q1
Discussions regarding trade issues affecting the pharmaceutical industry
Discussions regarding the Affordable Care Act (ACA) Discussions regarding insurance exchanges Discussions related to the Food Drug Cosmetic Act
Discussions regarding budget
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2014 · fourth_quarter · Q4
Discussions regarding medicare and medicaid 340B drug discount program
Discussions regarding Affordable Care Act (ACA) and the Food Drug Cosmetic Act (FDCA) Discussions regarding insurance exchanges
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2014 · third_quarter · Q3
Discussions regarding the Affordable Care Act (ACA), insurances exchanges, and Food, Drug Cosmetics Act (FDCA)
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2014 · second_quarter · Q2
Discussions regarding Medicare Part D Discussions regarding 340B program, Affordable Care Act (ACA)
Filing targets: SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2014 · first_quarter · Q1
Discussions regarding Medicare Part D Discussions regarding 340B program, Affordable Care Act (ACA)
Discussions regarding federal budget Discussions regarding Food, Drug & Cosmetics Act (FD&C)
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2013 · fourth_quarter · Q4
Discussions regarding Medicare Part D Discussions regarding 340B program, Affordable Care Act (ACA)
Discussions regarding federal budget Discussions regarding Food and Drug Administration user fees and PDUFA Discussions regarding the Sustainable Growth Rate (SGR)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2013 · third_quarter · Q3
Discussions regarding Medicare Part D Discussions regarding 340B program, Affordable Care Act (ACA), and Drug Quality & Security Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2013 · second_quarter · Q2
Discussions regarding healthcare reform; drug product tracking and supply chain issues Discussions regarding federal budget
Discussions regarding Medicare Part D Discussions regarding 340B program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2013 · first_quarter · Q1
Discussions regarding Medicare Part D
Discussions related to drug importation and IPAB
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2012 · fourth_quarter · Q4
Discussions related to drug importation; Discussions regarding healthcare reform; Discussions regarding the Food and Drug Administration user fees and issues regarding drug distribution.
Discussions regarding Medicare Part D including rebates for deficit reduction Discussions regarding 340B program Discussions regarding sequestration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2012 · third_quarter · Q3
Discussions related to drug importation and IPAB; Discusions regarding Prescription Drug User Fee Act (PDUFA) (no bill #); Discussions regarding healthcare reform; Discussions regarding the Food and Drug Administration Reform Act (H.R. 5651); Discussions regarding Drug Safety and Accountability Act (S.1584)
Discussions regarding Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2012 · first_quarter · 1A
Discussions regarding intellectual property protection and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2012 · second_quarter · Q2
Discussions related to drug importation and IPAB; Discusions regarding Prescription Drug User Fee Act (PDUFA) (no bill #); Discussions regarding healthcare reform; Discussions regarding the Food and Drug Administration Reform Act (H.R. 5651); Discussions regarding the Food and Drug Administration Safety and Innovation Act (S.3187).
Discussions regarding Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2012 · first_quarter · Q1
Discussions regarding intellectual property protection and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2011 · fourth_quarter · Q4
Discussions regarding intellectual property protection and innovation. Discussions related to patent settlements (S. 27)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2011 · third_quarter · Q3
Discussions regarding intellectual property protection and innovation. Discussions related to patent settlements (S. 27)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2011 · second_quarter · Q2
Discussions regarding patent reform, intellectual property protection, innovation and patent settlements (S. 23)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2011 · first_quarter · Q1
Discussions regarding patent reform, innovation and patent settlements (S. 23, S.319, S.27)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2010 · first_quarter · 1A
H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R. 3590 - The Patient Protection and Affordable Care Act; issues relating to drug importation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2010 · second_quarter · Q2
H.R. 759 - Food and Drug Administration Globalization Act of 2009, all provisions H.R. 4985 - Medicare Decisions Accountability Act of 2010, all provisions Discussions regarding drug product importation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2010 · first_quarter · Q1
H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R. 3590 - The Patient Protection and Affordable Care Act; issues relating to drug importation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2009 · fourth_quarter · Q4
H.R. 3200 - America's Affordable Health Choices Act of 2009, provisions related to importation of drugs; H.R. 3962 - Affordable Care for America Act, provisions related to dual eligibles, medicaid rebates, 340B, biosimilars; H.R.2502 - Comparative Effectiveness Research Act of 2009, all provisions; S. 525 - Pharmaceutical Market Access and Drug Safety Act of 2009, provisions related to drug importation; H.R. 3590 - The Patient Protection and Affordable Care Act; S.1796 - America's Healthy Future Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2009 · second_quarter · Q2
S. 982 - Family Smoking Prevention & Tobacco Control Act (issues related to drug product importation amendment) General issues related to drug product importation
General Health issues related to drug product importation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2008 · third_quarter · Q3
Drug product access and pricing
Product importation
Filing targets: HOUSE OF REPRESENTATIVES
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2007 · year_end · YA
Issues related to drug product access and pricing
Issues related to product importation
Issues related to patent reform relative to patent litigation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2007 · mid_year · MA
Issues related to The Patent Reform Act
Issues related to the Prescription Drug User Fee Act [PDUFA], and the FDA Modernization Act of 1997 [FDAMA], as they may relate to follow-on biologics and drug safety.
Issues related to pharmaceutical importation.
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2007 · year_end · YY
Issues related to patent reform relative to patent litigation
Issues related to drug product access and pricing
Issues related to product importation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2007 · mid_year · MM
Issues related to pharmaceutical importation.
Issues related to The Patent Reform Act.
Issues related to non-interference and pricing.
Discussions regarding drug importation 340B Drug Discount Program Drug User Fee Act
Discussions regarding the Bayh Dole Act
Discussions regarding Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to non-interference and pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Prescription Drug User Fee Act [PDUFA], and the FDA Modernization Act of 1997 [FDAMA], as they may relate to follow-on biologics and drug safety.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE